Aligos Therapeutics Inc Forecast, price target & analysts
Aligos Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Aligos Therapeutics Inc Classifications & Recommendation
Aligos Therapeutics Inc Price Target
| Target Price | $45.90 |
| Price | $5.24 |
| Potential |
775.95%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Aligos Therapeutics Inc 2027 .
The average Aligos Therapeutics Inc target price is $45.90.
This is
775.95%
register free of charge
$183.75
3,406.68%
register free of charge
$20.20
285.50%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Aligos Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aligos Therapeutics Inc stock has an average upside potential 2027 of
775.95%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.19 | 36.71 |
| 44.56% | 1,576.39% | |
| EBITDA Margin | -3,975.34% | -258.41% |
| 87.09% | 93.50% | |
| Net Margin | -1,104.57% | -117.05% |
| 66.75% | 89.40% |
10 Analysts have issued a sales forecast Aligos Therapeutics Inc 2026 . The average Aligos Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Aligos Therapeutics Inc EBITDA forecast 2026. The average Aligos Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Aligos Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Aligos Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.45 | -6.89 |
| 88.30% | 181.22% | |
| P/E | negative | |
| EV/Sales | 0.07 |
10 Analysts have issued a Aligos Therapeutics Inc forecast for earnings per share. The average Aligos Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Aligos Therapeutics Inc...
Current Aligos Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Lake Street |
Locked
➜
Locked
|
Locked | May 28 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 21 2026 |
| WestPark Capital |
Locked
➜
Locked
|
Locked | Mar 26 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 11 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Jan 07 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Lake Street:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 21 2026 |
|
Locked
WestPark Capital:
Locked
➜
Locked
|
Mar 26 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 11 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Jan 07 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
